|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's range||64.38 - 65.96|
|52-week range||57.17 - 74.12|
|Beta (5Y monthly)||0.33|
|PE ratio (TTM)||20.02|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||2.92 (4.47%)|
|Ex-dividend date||14 Sept 2022|
|1y target est||71.40|
Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day.
SANTA MONICA, Calif., October 03, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Viral vectors are key components needed to manufacture Kite’s cell therapies to treat certain blood cancers. Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, au
The healthcare industry is a great place to start. Let's examine two biotechs that seem to be able to do that: Gilead Sciences (NASDAQ: GILD) and CRISPR Therapeutics (NASDAQ: CRSP). Gilead Sciences is a leader in the market for HIV drugs although the company has recently faced some headwinds in this space.